# Integrative profiling of Helicobacter pylori clinical isolates: virulence genes, antimicrobial susceptibility and genetic diversity in gastric cancer risk stratification

**Authors:** Ying Zhang, Yanyan Shang, Zhenkai Li, Zupeng Kuang, Shixuan Huang, Qinghua Ye, Jianhui Chen, Zhixin Huang, Ling Chen, Ying Li, Qingping Wu

PMC · DOI: 10.1099/mgen.0.001599 · Microbial Genomics · 2026-03-04

## TL;DR

This study explores how different Helicobacter pylori strains contribute to gastric cancer risk by analyzing their genetic makeup, virulence factors, and antibiotic resistance.

## Contribution

The study integrates genomic, phenotypic, and clinical data to identify genetic markers and resistance patterns linked to gastric cancer risk in East Asia.

## Key findings

- Most isolates belonged to the East Asian lineage and carried high-risk virulence markers.
- Multidrug resistance was common, with high resistance to metronidazole and levofloxacin.
- Genome-wide association study identified five SNPs significantly associated with gastric cancer risk.

## Abstract

Background. Helicobacter pylori infection is a major risk factor for gastric cancer (GC), especially in East Asia. However, the mechanisms through which bacterial strain heterogeneity contributes to GC risk remain poorly understood. This study aims to elucidate the roles of specific virulence factors, antibiotic resistance profiles and genetic variations in H. pylori in GC development.

Methods. We integrated host clinical data with phenotypic and genomic analyses of 31 clinical H. pylori isolates. Genomic analysis was performed to determine phylogenetic lineage and virulence markers. Antibiotic susceptibility and biofilm-forming ability of the clinical isolates were also assessed, and a genome-wide association study (GWAS) was employed to identify genetic polymorphisms linked to GC risk.

Results. Among the isolates, 93.5 % of isolates belonged to the East Asian lineage and carried high-risk virulence markers (cagA EPIYA-ABD, vacA s1m1). However, multidrug resistance was observed in 64.5 % of isolates, with high resistance rates to metronidazole (71.0%) and levofloxacin (48.4%) exceeding global averages. Strong biofilm-forming strains were significantly associated with tetracycline resistance compared to weak biofilm-forming strains. Additionally, GWAS identified five SNPs significantly associated with GC risk, with variants in hemC, babB and C694_RS04850 being enriched in high-risk strains.

Conclusions. This study demonstrates the critical impact of H. pylori strain diversity in GC development, emphasizing the necessity for region-specific surveillance and innovative therapeutic strategies.

## Linked entities

- **Genes:** S100A8 (S100 calcium binding protein A8) [NCBI Gene 6279], vacA (prohibitin domain-containing protein) [NCBI Gene 8627181], HEMC (hydroxymethylbilane synthase) [NCBI Gene 830724], babB (Hop family adhesin BabB) [NCBI Gene 93237623]
- **Chemicals:** metronidazole (PubChem CID 4173), levofloxacin (PubChem CID 149096), tetracycline (PubChem CID 54675776)
- **Diseases:** gastric cancer (MONDO:0001056)
- **Species:** Helicobacter pylori (taxon 210)

## Full-text entities

- **Genes:** hemC [NCBI Gene 7909], CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, MUC5AC (mucin 5AC, oligomeric mucus/gel-forming) [NCBI Gene 4586] {aka MUC5, TBM, leB, mucin}, CagA [NCBI Gene 48200769], DCLK3 (doublecortin like kinase 3) [NCBI Gene 85443] {aka CLR, DCAMKL3, DCDC3C, DCK3}, OMP (olfactory marker protein) [NCBI Gene 4975], VacA [NCBI Gene 48201093]
- **Diseases:** GC (MESH:D013274), mucosal damage (MESH:D052016), OMPs (MESH:D015433), non-atrophic gastritis (MESH:D005757), chronic inflammation (MESH:D007249), gastric lesions (MESH:D013272), antibiotic (MESH:D004761), multidrug (MESH:D018088), gastric carcinogenesis (MESH:D063646), AMR (MESH:C565965), H. pylori infection (MESH:D016481), Cancer (MESH:D009369), peptic ulcers (MESH:D010437), TET (MESH:C535269), Gastritis (MESH:D005756), infected (MESH:D007239), atrophy (MESH:D001284), duodenal ulcer (MESH:D004381)
- **Chemicals:** CO2 (MESH:D002245), crystal violet (MESH:D005840), porphyrin (MESH:D011166), ATCC 43504 (-), clarithromycin (MESH:D017291), TET (MESH:D013752), LVX (MESH:D064704), glycerol (MESH:D005990), acetic acid (MESH:D019342), pyridoxal 5'-phosphate (MESH:D011732), N2 (MESH:D009584), PBS (MESH:D007854), MTZ (MESH:D008795), ethanol (MESH:D000431), fluoroquinolones (MESH:D024841), AMX (MESH:D000658), agar (MESH:D000362), nitroimidazoles (MESH:D009593)
- **Species:** Helicobacter pylori (species) [taxon 210], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** CNP0008421 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_SJ41)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12959884/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12959884/full.md

## References

71 references — full list in the complete paper: https://tomesphere.com/paper/PMC12959884/full.md

---
Source: https://tomesphere.com/paper/PMC12959884